GSK3326595: Phase I started

GlaxoSmithKline began an open-label, U.S. Phase I trial of oral GSK3326595. A dose-escalation portion will evaluate 12.5-400 mg GSK3326595 once or twice daily in up to 42 patients with relapsed and/or...